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Summary
Background Uveitis associated with juvenile idiopathic arthritis is a cause of major ocular morbidity. A substantial 
proportion of children are refractory to systemic methotrexate and TNF inhibitors. Our aim was to study the safety and 
efficacy of tocilizumab in children with juvenile idiopathic arthritis-associated uveitis refractory to both methotrexate 
and TNF inhibitors.
Methods This multicentre, single-arm, phase 2 trial was done following a Simon’s two-stage design at seven tertiary 
hospital sites in the UK. Patients aged 2–18 years with active juvenile idiopathic arthritis-associated uveitis were 
eligible. All patients had been on a stable dose of methotrexate for at least 12 weeks and had not responded to 
treatment with a TNF inhibitor. Patients weighing 30 kg or more were treated with 162 mg subcutaneous tocilizumab 
every 2 weeks for 24 weeks, and participants weighing less than 30 kg were treated with 162 mg every 3 weeks for 
24 weeks. The primary outcome was treatment response defined as a two-step decrease, or decrease to zero, from 
baseline in the level of inflammation (anterior chamber cells) at week 12, per the standardisation of uveitis 
nomenclature criteria. A phase 3 trial would be justified if more than seven patients responded to treatment. An 
interim analysis was planned to assess whether the trial would be stopped for futility, with futility defined as two or 
fewer treatment responses among ten participants. Adverse events were collected up to 30 calendar days after 
treatment cessation. The primary analysis was done in the intention-to-treat population and the safety analysis was 
done in all patients who started the treatment. This trial is registered with the International Standard Randomised 
Controlled Trial Number registry (ISRCTN95363507) and EU Clinical Trials Register (EudraCT 2015-001323-23).
Findings 22 participants were enrolled to the trial between Dec 3, 2015, and March 9, 2018, and 21 participants received 
treatment. One participant was found to be ineligible immediately after enrolment and was therefore withdrawn. 
Seven of 21 (median unbiased estimate of proportion 34% [95% CI 25–57]) responded to treatment (p=0·11). Safety 
results were consistent with the known safety profile of tocilizumab.
Interpretation The primary endpoint was not met, and thus the results do not support a phase 3 trial of tocilizumab 
in patients with juvenile idiopathic arthritis-associated uveitis. Importantly, data on the use of tocilizumab in clinical 
practice is now captured in national registries. Despite this trial not meeting the threshold required to justify a larger 
phase 3 trial, several patients responded to treatment; as such, tocilzumab might still be a therapeutic option in some 
children with uveitis refractory to anti-TNF drugs, given the absence of other treatment options.
Funding Versus Arthritis and the National Institute for Health Research Clinical Research Network: Children.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Juvenile idiopathic arthritis is an inflammatory arthritis 
that affects one in 1000 children. Children with juve nile 
idiopathic arthritis are also at risk of uveitis, an inflam­
mation of the uvea in the eye. Up to 80% of all paedi atric 
uveitis is secondary to juvenile idiopathic arthritis.1,2 The 
development of juvenile idiopathic arthritis with uveitis 
is associated with early onset of arthritis, an oligoarticu­
lar pattern of arthritis, and presence of anti nuclear 
antibodies.3
Children with moderate to severe uveitis can be 
refractory to methotrexate.4–8 In such patients, mono­
clonal TNF inhibitors, including adalimumab, are often 
effective.9–12 However, 30–40%13 of patients are refractory 
to both methotrexate and TNF inhibitors and are there­
fore at great risk of significant ocular complications and 
blindness.
In patients with severe disease that does not respond to 
methotrexate and anti­TNF drugs, strong evidence sup­
ports the approach of targeting interleukin­6 (IL­6) in the 
disease pathogenesis.14–18 Therefore, a phase 2 trial of 
the potential efficacy, safety, and tolerability of the IL­6 
receptor inhibitor tocilizumab was done. In arthritis, 
IL­6 causes tiredness, anaemia, and inflammation, as well 
as dam age to bones, cartilage, and tissue; tocilizumab 
reduces these effects.19 Previous studies looking at the 
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effect of tocilizumab in children have been done looking 
at rheumatological examinations only.20 However, in a trial 
of tocilizumab in children with the systemic form of juve­
nile idiopathic arthritis who are unresponsive to metho­
trexate, patients responded dramatically to treatment in a 
short time span.20 As a result, tocilizumab became the first 
drug licenced for use in juvenile idiopathic arthritis in 
50 years; tocilizumab also obtained National Institute for 
Health and Care Excellence approval for this indication 
in 2011. An ongoing clinical trial is test ing tocilizumab 
in patients with polyarticular forms of juvenile idio­
pathic arthritis with good effect (NCT02165345). How­
ever, patients with juvenile idiopathic arthritis­associated 
uveitis have been excluded from these clinical trials, so 
the efficacy of tocilizumab in these patients is unclear. 
There fore, in the APTITUDE trial, we aimed to assess 
the safety and efficacy of tocilizumab in this paediatric 
population.
Methods
Study design
APTITUDE was a multicentre, single­arm, phase 2 trial 
that was done at seven tertiary hospital sites in the UK 
following a Simon’s two­stage design,21 in which a small 
group of participants are recruited in the first stage, and 
the recruitment of another group of participants in stage 
2 only commences if an adequate number of responses 
have been observed in the first stage (appendix p 1).
Ethical approval for the trial was provided by the 
National Research Ethics Service Committee London—
South East on July 3, 2015 (reference number 15/LO/0771).
The protocol and statistical analysis plan are available 
online.
Patients
Children and young people aged 2–18 years of age who 
had active juvenile idiopathic arthritis­associated uveitis 
were eligible to take part in the trial. Active uveitis was 
defined based on the standardisation of uveitis nomen­
clature (SUN) criteria22 as two or more readings of cellular 
infiltrate in anterior chamber cells of grade 1+ or greater 
(possible scores are 0, 0·5+, 1+, 2+, 3+, and 4+) during the 
6 weeks preceding screening. Participants must have had 
an inadequate treatment response with at least one anti­
TNF drug and have been on at least one anti­TNF drug 
(regardless of dose) for at least 12 weeks at any time 
before enrolment in the trial. They must have been on 
methotrexate for at least 12 weeks with a stable dose for 
4 weeks before screening, without adequate response. 
Key exclusion criteria were previous exposure to tocili­
zumab; previous exposure in a clinical trial to another 
medicinal product such that the estimated level of the 
drug in the patient’s blood was more than that predicted 
by 4 weeks or five half­lives of the drug (whichever was 
longer); receipt of more than six topical glucocorticoid 
drops per eye per day at time of enrolment; and receipt 
of prednisone (or the equivalent) at a dose exceeding 
0·2 mg/kg bodyweight per day. Patients who did not pass 
screening were able to be re­screened after a minimum 
of 1 week after their last screening. Full exclusion criteria 
are in the appendix (p 3). Each parent or guardian pro­
vided written informed con sent. Each child gave assent 
when appropriate.
Procedures
Patients received tocilizumab dosed according to body­
weight, with patients weighing 30 kg or more given 
Research in context
Evidence before this study
We reviewed an evidence synthesis review update in April, 
2013, and before grant submission, prepared by Arthritis 
Research UK (now Versus Arthritis). The object of this report 
was to highlight recently completed and ongoing clinical trials 
in Paediatric Rheumatology. We found no studies related to 
tocilizumab and juvenile idiopathic arthritis-associated uveitis. 
We also searched ClinicalTrials.gov using the search terms 
“uveitis” and “tocilizumab”. We found one open-label trial 
aiming to assess tocilizumab treatment in six patients with 
juvenile idiopathic arthritis-associated uveitis. The efficacy of 
tocilizumab in uveitis and ophthalmology outcomes had not 
been assessed before that study. However, the rationale for 
anti-IL-6 therapy is strong—in arthritis, IL-6 causes tiredness, 
anaemia, and inflammation and damage to bones, cartilage, 
and tissue. Tocilizumab blocks IL-6, reducing the symptoms. 
Hence, a phase 2 study is needed to give early indications of the 
clinical effectiveness of tocilizumab in combination with 
methotrexate and to decide whether further research is 
justified. Previous studies investigating the effect of 
tocilizumab in paediatric arthritis have excluded patients with 
uveitis. However, a study by Muselier and colleagues on 
tocilizumab in uveitis in adults showed its potential role for 
refractory disease. A previous systematic search by Adán and 
colleagues of existing data found only a couple of case reports.
Added value of this study
To our knowledge, this is first trial looking at efficacy of 
tocilizumab in juvenile idiopathic arthritis-associated uveitis. 
This study is able to give early indications of the potential 
clinical effectiveness of tocilizumab in combination with 
methotrexate for the treatment of children with refractory 
juvenile idiopathic arthritis-associated uveitis.
Implications of all the available evidence
This study provides evidence that tocilizumab might be a useful 
adjunctive therapeutic option for children with uveitis 
refractory to anti-TNF treatments. This study also provides 
evidence of efficacy in macular oedema associated with juvenile 
idiopathic arthritis uveitis, as reported in previous studies.
For the protocol and statistical 
analysis plan see 
http://www.uhbristol.nhs.uk/
research-innovation/our-
research/grants-and-
infrastructure-awards/
large-charitable-grants/aptitude/
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162 mg of subcutaneous tocilizumab every 2 weeks and 
patients weighing less than 30 kg given 162 mg of sub­
cutaneous tocilizumab every 3 weeks for 24 weeks. 
Patients weighing less than 30 kg were given a maximum 
of nine injections and patients weighing 30 kg or more 
were given a maximum of 13 injections. Injections were 
administered at hospital or by self administration at 
home depending on patient preference. Patients who 
missed two consecutive doses or three doses in total of 
tocilizumab injection ceased trial treatment and were 
recorded as a withdrawal from treatment. Treat ment 
compliance was measured using accountability logs and 
participant diaries. All participants were treated up to a 
maximum of 24 weeks and then followed up after 
treatment for 12 weeks and assessed per the trial assess­
ments (appendix p 2). All patients continued on metho­
trexate throughout trial participation.
Adverse events were collected up to 30 calendar days 
after cessation of treatment. Patients who did not achieve 
treatment response stopped treatment and proceeded to 
follow­up.
Outcomes
The primary outcome was response to treatment, defined 
according to SUN criteria22 as a two­step decrease in 
score in the level of inflammation (anterior chamber 
cells) or decrease to zero between baseline and 12 weeks 
of treatment. Secondary outcomes included safety and 
tolerability of tocilizumab; compliance; corticosteroid 
use; optic and ocular outcomes; quality of life; American 
College of Rheumatology (ACR) pediatric 30, ACR 
pediatric 50, ACR pediatric 70, ACR pediatric 90, and 
ACR pediatric 100; numbers of participants with changes 
in biologic or disease­modifying anti­rheumatic drugs; 
numbers of patients with arthritis flares; and juvenile 
arthritis disease activity score (JADAS). Details are in the 
appendix (pp 4–5).
Statistical analysis
The trial was done following a Simon’s two­stage design.21 
The null hypothesis (response 20% or lower) reflected a 
response rate of no clinical benefit whereas the alternative 
hypothesis (response at least 50%) reflects a desired 
response. If the true success probability was 20%, then the 
probability of success in further study of tocilizumab 
would be less than 5% (ie, falsely pursuing a non­
promising therapy). If the true success probability was 
50% or more, then further study of tocilizumab in a phase 
3 trial would be recommended, with a probability greater 
than 90% of showing a therapeutic effect of the drug (ie, 
correctly pursuing a promising therapy).
The interim and final sample sizes and the critical values 
for abandoning tocilizumab at each stage were chosen a 
priori as follows: the interim analysis sample size was ten 
patients, and the analysis was done after ten patients had 
provided primary outcome data at the 12­week visit. Based 
on a critical interim value of two treatment responses (ie, if 
there were two or fewer treat ment responses then the trial 
would be stopped for futility), a sample size of 22 patients 
was needed for the full analysis, with a critical value of 
seven treatment responses (ie, if there were seven or fewer 
treatment responses, then it would be concluded that 
the further study of tocilizumab should be abandoned). 
If further study of the drug is not abandoned at either 
the interim or the final analysis, then a recommendation 
would be made to conduct a comparative, randomised 
phase 3 trial. The interim analysis was reviewed by the 
independent safety monitoring committee, who made 
recommendations to the trial steering committee whether 
to continue the trial or terminate it for futility.
Analyses was done according to the predefined statistical 
analysis plan and used the principle of intention to treat. If 
consent to treatment was withdrawn but the participant 
agreed to remain in the study for follow­up, the partici­
pant was followed up until 12 weeks after ceasing trial 
treatment. If the participant decided to withdraw consent 
completely, the reasons for withdrawal of consent were 
recorded (if possible) and reported.
For the primary outcome, the point estimate, CI, and p 
value were computed using the method described by 
Jovic and Whitehead.23 Prespecified sensitivity analy ses 
tested the effects of missing data, participants who 
stopped their intervention early, and those who had 
been incorrectly identified as having treatment response. 
Trial oversight was provided by an independent data 
and safety monitor ing committee and a trial steering 
committee.
All analyses were done with SAS, version 9.3 or 
above. The trial was registered on the International 
Standard Randomised Controlled Trial Number registry 
(ISRCTN95363507) on June 10, 2015, and EU Clinical 
Trials Register on July 3, 2015 (EudraCT 2015­001323­23).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
the data in the study and had final responsibility for the 
decision to submit for publication.
Results
Patients were recruited for the trial between Dec 3, 2015, 
and March 9, 2018. 44 patients were screened (58 screen­
ing events) at seven tertiary hospital sites in the UK 
(appendix p 20). 24 patients (32 screenings) did not meet 
the inclusion criteria and 26 patients met the inclusion 
criteria (six of these patients were deemed eligible after 
not meeting inclusion criteria at an earlier visit; figure). 
The main reasons for ineligibility were absence of active 
anterior uveitis as defined in the protocol (17 [53%] 
of 32 screening events) and presence of clinically signi­
ficant deviations in laboratory parameters (four [13%]; 
appendix p 6). Four patients did not consent to take part in 
the trial. 22 participants were enrolled in the trial.
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Particpants were aged 5–17 years and 18 (86%) were 
women (table 1). All participants in the study had taken 
adalimumab and none had received other TNF inhibitors; 
additional demographic and baseline clinical information 
are in the appendix (pp 6–8). Data for the primary 
outcome were available for all the participants except 
one, who was found to be ineligible immediately after 
enrolment; this patient was therefore not included in any 
of the analyses. 17 (81%) of 21 patients discontinued 
treatment before 24 weeks, six (29%) discontinued before 
their 12­week visit, nine (43%) discontinued at 12 weeks, 
and two (10%) discontinued between weeks 12 and 24 
(one because of non­response and the other because of a 
requirement for a non­permitted medication to treat 
worsening ocular pressures). Treatment compliance was 
92% according to the patient diaries and 80% according 
to accountability logs.
The results of the interim analysis were reported 
to the independent safety monitoring committee in 
November, 2016. Four (40%) of ten participants responded 
to treatment, indicating that the trial should continue.
Seven (33%) of 21 participants achieved treatment res­
ponse at week 12 (table 2). The median unbiased estimate 
of the proportion of treatment responses was 34% (95% CI 
25–57; p=0·11). Of the six patients that discontinued 
treatment before week 12, one was classified as a treatment 
res ponse and the other five as non­responders. 13 (62%) 
of 21 patients were classified as non­responders, eight of 
whom reached 12 weeks of treatment. Of the six patients 
who continued treatment after 12 weeks, four (67%) were 
classed as treatment responders at 24 weeks.
The safety data set consisted of all 21 patients who 
received at least one dose of the study drug. A total of 
175 adverse events were reported in 20 (95%) participants; 
no serious adverse events were reported during the trial 
(appendix pp 8–10). 21 adverse events of special interest 
in seven (33%) patients were collected during the trial 
(appendix p 10). The most frequent adverse events were 
injection site reaction (24 events in eight [38%] patients), 
arthralgia (eight events in four [19%] patients), and 
headache (eight events in five [24%] patients; table 3). 
Safety results were consistent with the known safety 
profile for tocilizumab.
Secondary outcome results are in the appendix (pp 10–18). 
Of 21 participants, four (19%) were receiving oral cortico­
steroids at baseline. Three of these patients were taking 
5 mg per day or more at baseline, and none were able to 
reduce the dose to less than 5 mg per day (appendix p 10). 
20 patients were using topical cortico steroid eye drops at 
baseline, 18 of whom who were on two or more drops per 
eye per day (appendix p 11). Three (17%) of these 18 patients 
were able to reduce use to less than two drops per eye per 
day. Three (15%) of 20 participants were able to completely 
stop use of corticosteroid eye drops.
Four (19%) patients had macular oedema at base­
line, which resolved after treatment in three patients. 
Two patients had glaucomatous neuropathy at baseline; 
this resolved during the course of the trial in one patient 
and the other patient developed neovascularisation, which 
subsequently resolved. No participants had complete dis­
ease control (as defined by SUN criteria22 as zero cells) at 
Figure: Trial profile
*Patients could be screened multiple times; six of these patients were ineligible 
at an earlier visit.
44 patients screened (58 screening events)
26 eligible* (26 screening events)
24 ineligible (32 screening events)
22 patients enrolled
4 did not provide consent
21 received intervention
1 ineligible so did not receive intervention
4 completed 24 weeks treatment and 12 weeks follow-up 
21 in intention-to-treat analysis 
17 discontinued
 5 discontinued tocilizumab before 12 weeks and continued 
          12 weeks follow-up
 1 discontinued tocilizumab prior to 12 weeks and withdrew from 
  trial
 9 discontinued tocilizumab at 12 weeks and continued 12 weeks 
  follow-up
 2 discontinued tocilizumab between weeks 12 and 24 and 
  continued 12 weeks follow-up
Tocilizumab (n=21)
Number of study eyes
Unilateral 13 (62%)
Bilateral 8 (38%)
Age at enrolment, years
Mean (SD) 12·3 (3·5)
Median (IQR) 12·8 (10·4–15·1)
Range 5·4–17·3
Sex
Female 18 (86%)
Male 3 (14%)
Weight, kg
<30 6 (29%)
≥30 15 (71%)
Data are n (%) unless otherwise stated.
Table 1: Baseline demographic details
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week 12 or week 24 with topical treatment and sub­
cutaneous tocilizumab.
Quality of life data as measured by the child health 
questionnaire and childhood health assessment question­
naire were not clinically significant and arthritis disease 
activity measures (ACR pediatric and JADAS) scores did 
not change significantly (appendix pp 14–16).
In a post­hoc analysis, three (19%) patients had a partial 
response (one­step improvement) at the 24­week visit 
(two patients had 12 weeks of treatment and one had 
11 weeks).
The mean number of corticosteroid drops at baseline 
was 4·48 drops (SD 3·11), which reduced to 4·33 drops 
(2·29) at 12 weeks (appendix p 11). Foveal thickness split 
was also assessed post­hoc and the mean number for best 
score was 278·6 (SD 67·68) reducing to 257·7 (51·73) at 
24 weeks (appendix p 17).
Discussion
This Simon’s two­stage design study of participants 
with treatment refractory juvenile idiopathic arthritis­
associated uveitis did not meet the prespecified criterion 
(more than seven responses from 21 partici pants) at 
12 weeks to justify a phase 3 trial. A third of the participants 
(seven [33%] of 21) had a two­step improvement in uveitis 
assessment at week 12 and a further three (14%) had a 
one­step improvement at week 24 with tocilizumab. Three 
of four participants had complete resolution of cystoid 
macular oedema in response to tocilizumab.
Tocilizumab is effective in polyarticular20 and systemic 
juvenile idiopathic arthritis24 as well as rheumatoid 
arthritis25 and giant cell arteritis.26 The STOP­Uveitis 
study,14 an open­label study of intravenous tocilizumab in 
adult patients with posterior segment uveitis, showed 
a red uction in vitreous haze and macular thickness. 
Improve ments in anterior chamber cell counts and 
macular thickening were seen in retrospective studies of 
intra venous tocilizumab in juvenile idiopathic arthritis 
uveitis and adult uveitis, including adult juvenile idio­
pathic arthritis.15–18
One study of tocilizumab in juvenile idiopathic arthritis 
used the juvenile idiopathic arthritis ACR pediatric 30 
response at 12–16 weeks as the primary outcome,20 which 
although not directly comparable to uveitis scores, are 
arguably a less robust response than a two­step decrease 
on the SUN inflammation score. Studies have also 
shown progressive improvements in uveitis activity14 over 
26 weeks and systemic juvenile idiopathic arthritis 
disease activity over 52 weeks24 with tocilizumab. It is 
possible that the number of responders on tocilizumab 
would have been higher with a longer duration of treat­
ment, but it is also important to protect against the 
risks of a potentially ineffective treatment. Rapid disease 
control is important in uveitis, in which prolonged uveitis 
activity increases the risk of sight loss.27
Subcutaneous tocilizumab was less effective than 
intravenous tocilizumab for juvenile idiopathic arthritis 
uveitis in a small case series,28 but has shown similar 
efficacy to intravenous tocilizumab in randomised con­
trolled studies of rheumatoid arthritis.29,30 Subcutaneous 
therapies are more desirable than intravenous infusions 
for patient convenience, maximising school attendance 
and using fewer health­care resources. The eye has blood 
aqueous and blood retinal barriers and so potentially 
higher doses of drug are required in the eye to gain 
therapeutic efficacy than at other body sites.31
The paucity of clinical trials for paediatric uveitis 
combined with the availability of potential treatments 
Eligible eye Response eye Right eye SUN grade Left eye SUN grade
Baseline 12 weeks Baseline 12 weeks
1 Both Both 2+ 0·5+ 2+ 0·5+
2 Both Both 3+ 0 3+ 0·5+
3 Both Both 3+ 1+ 3+ 0·5+
4 Left Left NA NA 4+ 0·5+
5* Left Left NA NA 2+ 0
6 Both Both 2+ 0·5+ 2+ 0·5+
7 Right Right 4+ 1+ NA NA
A response was defined as a two-step decrease in SUN22 grade or decrease to 0. NA=not applicable. 
SUN=standardisation of uveitis nomenclature. *Withdrew from treatment after the week 8 visit and assessed by 
committee to be a responder at 8 weeks.
Table 2: Responders
Grade 1–2 
(≥10% patients)
Grade 3  
(all)
Eye disorders
Uveitis 2; 2 (10%) 1; 1 (5%)
Gastrointestinal disorders
Vomiting 3; 3 (14%) 0;
General disorders and administration site conditions
Injection site reaction 24; 8 (38%) 0
Infections and infestations
Upper respiratory tract infection 3; 3 (14%) 0
Investigations
Alanine aminotransferase increased 4; 3 (14%) 0
Blood triglycerides increased 3; 3 (14%) 0
Intraocular pressure increased 3; 1 (5%) 1; 1 (5%)
Neutrophil count decreased 4; 3 (14%) 0
Musculoskeletal and connective tissue disorders
Arthralgia 8; 4 (19%) 0
Nervous system disorders
Headache 8; 5 (24%) 0
Respiratory, thoracic, and mediastinal disorders
Cough 7; 5 (24%) 0
Oropharyngeal pain 7; 6 (29%) 0
Data are number of events; number of patients (%). No grade 4 (life threatening) 
or grade 5 (deaths) events occurred. For adverse events reported as severe, any 
corresponding mild or moderate event that occurred in less than 10% of patients 
have also been presented.
Table 3: Grade 1–2 adverse events occurring in at least 10% of patients 
and all grade 3–5 events (n=21)
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through use in other rheumatic diseases has led to many 
immunosuppressive drugs being prescribed for paediatric 
uveitis and included in treatment guidelines with little 
evidence.32 A strength of this study is the incorporation of 
the Simon design to identify molecules for further clinical 
study in patients with paediatric uveitis, with low risk to 
participants, and to enable the gathering of evidence 
and publication of results in a more systematic way than 
in case series and open­label studies. Safety results were 
consistent with the known safety profile of intraven­
ous tocilizumab, with the exception of injection site 
reactions.20,24
Limitations of this study include the small sample size, 
absence of a control group, and severity of disease. With 
respect to severity of disease in this cohort, the patients 
enrolled displayed moderate anterior chamber inflam­
mation, and in some it was associated with cystoid 
macular oedema despite anti­TNF and methotrexate 
therapy. Continuing inflammation in the face of sub­
stantial immunomodulatory therapy indicates a cohort of 
patients with moderate to severe disease overall. The 
12­week duration of the primary outcome might have 
underestimated the treatment efficacy, and no uveitis­
specific patient­recorded outcome measures were used. 
Macular oedema outcomes were limited to presence or 
absence of oedema and central macular thickness, which 
might vary on different optical coherence tomography 
machines.33 Additionally, the results are not transferable 
to other formulations of tocilizumab and therefore the 
optimal method of administration for juvenile idiopathic 
arthritis­associated uveitis remains unclear. Finally, in 
this small study no stratification of molecular signatures 
was done to identify differences between responders and 
non­responders.
In conclusion, subcutaneous tocilizumab did not meet 
its primary endpoint in this Simon design study. Efficacy 
signals for juvenile idiopathic arthritis uveitis were noted, 
including reduction of macular oedema, as rep orted in 
previous studies, but not at a sufficient level to warrant a 
phase 3 study. There might be merit in studying intra­
venous formulations of tocilizumab in a select predefined 
population of patients.
Although this study used the standard and validated 
measure of anterior chamber cell activity to assess the 
extent of inflammation, lower levels of persistent inflam­
mation that are more quantifiable by clinical assessment 
might be more useful for trials and going forward in 
clinical practice. Laser flare photometry, for example, was 
adopted in the Adjuvite study.34
For patients with refractory uveitis not responsive to 
anti­TNF drugs, other therapeutic approaches have been 
reported anecdotally, including checking for anti drug 
antibodies, weekly adalimumab abatacept, and JAK­kinase 
inhibitors.35–37 Tocilizumab might provide a valuable 
adjunc tive therapeutic option for children with uveitis ref­
ractory to anti­TNF, particularly as adalimumab is the only 
evidence­based and licensed therapy. Although our study 
did not meet its primary endpoint, this is, to our know­
ledge, the only prospective study of tocilizumab.
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